ArticleOncotarget2016

Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients.

Sarah Cattin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.